NCT04980248View on ClinicalTrials.gov

Study of ALXN1850 in Participants With Hypophosphatasia (HPP)

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

August 24, 2022

Study Completion Date

August 24, 2022

Conditions
Hypophosphatasia
Interventions
BIOLOGICAL

ALXN1850

ALXN1850 will be administered as an IV infusion and via the SC route.

Trial Locations (4)

37232

Research Site, Nashville

43203

Research Site, Columbus

78744

Research Site, Austin

89113

Research Site, Las Vegas

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY